Shift and irregular-schedule workers are not a niche inside the wearable market — they are the segment every incumbent under-serves, because a diurnal model is baked into the product's core assumptions.
Phase estimation needs continuous distal temperature with ambient compensation. That is a hardware decision made at design time, and it trades directly against the optical sensing incumbents have already committed to.
Low-power thermistors, BLE 5.4 and small batteries are commodity. The circadian literature on temperature-derived phase is mature enough to build on without inventing the science first.
Growth has been entirely word of mouth inside units — no paid acquisition to date, which is both the encouraging part and the unproven part.
Cumulative pilot participants. Unaudited; Q3 2026 is partial.
The ring is priced to cover its own landed cost and fulfilment at modest volume, so subscription margin isn't subsidising a loss-leading device.
Runway to Q4 2028 at current burn, before revenue contribution.
Roughly one in five US workers is on a shift schedule. Every mainstream wearable models them as a broken day-shift user and tells them their sleep score is bad.
Circadian phase can't be added by software update — it needs continuous distal temperature, which no major ring or watch prioritises today.
Individuals buy the ring. Health systems and industrial operators buy fatigue-risk reduction, and already carry the cost of not having it.
Launching as a general wellness product puts no clearance gate on revenue, while the pilot base compounds into the evidence a clinical indication would need.
We would rather you hear these from us than find them in diligence.
Where most wellness products bleed out. Our cohorts hold at 74% at day 90; that number is small-n and we treat it as a hypothesis, not a result.
Tooling, yield and certification cost time we can't compress. We mitigate by shipping one SKU and refusing feature creep before GA.
A large player could add temperature-based phase estimation. Our defence is depth in one population and enterprise relationships they are slow to build.
Health systems move in budget years. Consumer revenue exists partly so the enterprise timeline can't kill us.
Everything to date is word of mouth inside units. Paid acquisition at a $74 CAC is a target, not an observed number.
The founder and Head of Science hold most of the domain credibility with pilot units. Hiring the science bench out is the explicit mitigation.
Current materials: validation summary, unit economics, enterprise pipeline and the full risk register.
Figures on this page are unaudited and describe pilot-stage operations. Nothing here is an offer to sell securities.